Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

키워드

참고문헌 (19)

1. Cameron Gofton, "MAFLD: How is it different from NAFLD?", Clinical and Molecular Hepatology, 29, pp.17~31 (2023), 대한간학회
2. Eslam M, "MAFLD : A consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
3. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
4. Méndez-Sánchez N, "Global multi-stakeholder endorsement of the MAFLD definition", Lancet Gastroenterol Hepatol, 7, pp.388~390 (2022)
5. Takumi Kawaguchi, "MAFLD enhances clinical practice for liver disease in the Asia-Pacific region", Clinical and Molecular Hepatology, 28(2), pp.150~163 (2022), 대한간학회[DOI]
6. Kim M, "Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea", Liver Int, 42, pp.1536~1544 (2022)
7. Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : A nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
8. Wong VW, "Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease", Clin Gastroenterol Hepatol, 19, pp.2161~2171 (2021)
9. Choi HSJ, "Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B", Hepatology, 71, pp.539~548 (2020)
10. Shang-Chin Huang, "Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives", Clinical and Molecular Hepatology, 29(2), pp.320~331 (2023), 대한간학회
11. Zheng Q, "Systematic review with meta-analysis : prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B", Aliment Pharmacol Ther, 54, pp.1100~1109 (2021)
12. Ng CH, "Examining the interim proposal for name change to steatotic liver disease in the US population", Hepatology (2023)[DOI]
13. Yoon Eileen L., "Waiting for Multi-Stakeholders’Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature", Gut and Liver, 16(3), pp.319~320 (2022), 거트앤리버 소화기연관학회협의회[DOI]
14. Younossi ZM, "From NAFLD to MAFLD : Implications of a premature change in terminology", Hepatology, 73, pp.1194~1198 (2021)
15. Eunji Ko, "Risk factors in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.79~85 (2023), 대한간학회
16. Silvia Sookoian, "Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response", Clinical and Molecular Hepatology, 29, pp.184~195 (2023), 대한간학회
17. Erica Jennison, "The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(1), pp.22~43 (2021), 대한간학회[DOI]
18. Sae Kyung Joo, "Interaction between sarcopenia and nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.68~78 (2023), 대한간학회
19. Dae Won Jun, "An analysis of polygenic risk scores for non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.446~447 (2021), 대한간학회[DOI]

관련 논문AI추천